Race Oncology Limited (RAONF)
USD 1.22
(0.0%)
USD 1.22
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 14.77 Million AUD | 16.25% |
| 2023 | 12.7 Million AUD | 9.45% |
| 2022 | 7.73 Million AUD | 66.24% |
| 2021 | 4.65 Million AUD | 83.6% |
| 2020 | 2.53 Million AUD | 3.67% |
| 2019 | 2.44 Million AUD | -45.59% |
| 2018 | 4.49 Million AUD | 54.39% |
| 2017 | 2.9 Million AUD | 687.28% |
| 2016 | 369.47 Thousand AUD | 447.11% |
| 2015 | 67.53 Thousand AUD | -24.79% |
| 2014 | 89.79 Thousand AUD | 647.59% |
| 2013 | 12.01 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 5.38 Million USD | 0.0% |
| 2024 Q2 | 6.44 Million USD | 0.0% |
| 2023 Q4 | 4.84 Million USD | 0.0% |
| 2023 FY | 8.46 Million AUD | 9.45% |
| 2023 Q2 | 3.69 Million USD | 0.0% |
| 2022 Q2 | 3.72 Million USD | 0.0% |
| 2022 FY | 7.73 Million AUD | 66.24% |
| 2022 Q4 | 4.18 Million USD | 0.0% |
| 2021 Q4 | 2.97 Million USD | 0.0% |
| 2021 FY | 4.65 Million AUD | 83.6% |
| 2021 Q2 | 1.72 Million USD | 0.0% |
| 2020 Q4 | 1.53 Million USD | 0.0% |
| 2020 Q2 | 1.01 Million USD | 0.0% |
| 2020 FY | 2.53 Million AUD | 3.67% |
| 2019 FY | 2.44 Million AUD | -45.59% |
| 2019 Q4 | 1.01 Million USD | 0.0% |
| 2018 FY | 4.49 Million AUD | 54.39% |
| 2017 FY | 2.9 Million AUD | 687.28% |
| 2016 FY | 369.47 Thousand AUD | 447.11% |
| 2015 FY | 67.53 Thousand AUD | -24.79% |
| 2014 FY | 89.79 Thousand AUD | 647.59% |
| 2013 FY | 12.01 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 82.98% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -200.34% |
| SQZ Biotechnologies Company | 85.61 Million USD | 82.749% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 50.02% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 60.354% |
| Mesoblast Limited | 5.9 Million USD | -150.262% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -883.453% |
| Genus plc | 147.7 Million USD | 90.0% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -68.243% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1001.005% |
| Marizyme, Inc. | 19.23 Million USD | 23.23% |
| ContraFect Corporation | 56.88 Million USD | 74.036% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -77.125% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -235.032% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -898.847% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -406.491% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -429.34% |
| MultiCell Technologies, Inc. | 567.42 USD | -2602993.652% |
| Accustem Sciences Inc. | 3.74 Million USD | -294.256% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 82.814% |
| EV Biologics, Inc. | 531.96 Thousand USD | -2676.603% |
| Q BioMed Inc. | 3.43 Million USD | -329.796% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 40.237% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -3691.52% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -462.145% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1385.691% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 93.45% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -119.864% |
| Skye Bioscience, Inc. | 13.54 Million USD | -9.027% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -620.966% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 59181.896% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -192.946% |
| IMV Inc. | 37.7 Million USD | 60.831% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 7.744% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -704.889% |
| GB Sciences, Inc. | 1.42 Million USD | -939.802% |
| Alpha Cognition Inc. | 9.7 Million USD | -52.185% |
| HST Global, Inc. | 140.9 Thousand USD | -10382.427% |
| CSL Limited | 3.44 Billion USD | 99.572% |
| Halberd Corporation | 74.84 Thousand USD | -19635.542% |
| Enzolytics Inc. | 2.17 Million USD | -577.698% |
| Resverlogix Corp. | 12.71 Million USD | -16.193% |
| Affymax, Inc. | 39.38 Million USD | 62.498% |
| SYBLEU INC | 160.87 Thousand USD | -9081.279% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -304.592% |
| argenx SE | 1.53 Billion USD | 99.037% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 74.285% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1314.796% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -835.222% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -333.79% |
| AVAX Technologies, Inc. | 7.31 Million USD | -102.051% |
| Zenith Capital Corp. | 8.94 Million USD | -65.162% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.21% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -84685.454% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -501.571% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -8512.069% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 85.13% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -739.385% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -648.997% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -692.25% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -35.92% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -668.933% |
| BioStem Technologies, Inc. | 22.97 Million USD | 35.71% |
| ONE Bio Corp. | 6.44 Million USD | -129.217% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -8038.675% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1006.045% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1213.036% |
| Agentix Corp. | 1.37 Million USD | -976.757% |
| LadRx Corporation | 3.81 Million USD | -287.494% |
| Cell Source, Inc. | 4.32 Million USD | -241.487% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -3455.047% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1499.384% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1499.384% |
| NovAccess Global Inc. | 2.46 Million USD | -498.78% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -514.174% |
| Itoco Inc. | 919.14 Thousand USD | -1506.983% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -248.491% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1219.971% |
| Kadimastem Ltd | 2.41 Million USD | -512.854% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -5543.487% |
| CytoDyn Inc. | 18.05 Million USD | 18.205% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -58585.184% |
| Mobile Lads Corp. | 554.54 Thousand USD | -2563.525% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -6611.472% |
| Qrons Inc. | 643.67 Thousand USD | -2194.703% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -940.327% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -562.389% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2124.469% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -713.209% |
| International Stem Cell Corporation | 5.27 Million USD | -180.221% |
| Bioxytran, Inc. | 3.82 Million USD | -286.647% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -27958.345% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -72507.157% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 59.272% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -812.885% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1907.308% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -374.782% |
| Neutra Corp. | 243.82 Thousand USD | -5957.917% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 15.389% |
| PureTech Health plc | 144.59 Million USD | 89.785% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 27.913% |
| IXICO plc | 4.7 Million USD | -213.798% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -67.904% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 87.456% |
| CSL Limited | 3.89 Billion USD | 99.621% |
| Cellectis S.A. | 97.32 Million USD | 84.823% |